bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant...Show More

bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant changes in its results of operations for the quarter ended March 31, 2024, compared to the same period in 2023, but it is currently unable to provide an estimate of these changes. The notification filed with the SEC also includes forward-looking statements and acknowledges that the company's 2023 Form 10-K has not yet been filed.